GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (OTCPK:TRSBF) » Definitions » LT-Debt-to-Total-Asset

3SBio (TRSBF) LT-Debt-to-Total-Asset : 0.05 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is 3SBio LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. 3SBio's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.05.

3SBio's long-term debt to total assets ratio declined from Jun. 2023 (0.13) to Jun. 2024 (0.05). It may suggest that 3SBio is progressively becoming less dependent on debt to grow their business.


3SBio LT-Debt-to-Total-Asset Historical Data

The historical data trend for 3SBio's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio LT-Debt-to-Total-Asset Chart

3SBio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.13 0.19 0.12 -

3SBio Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.13 0.12 0.05 -

3SBio LT-Debt-to-Total-Asset Calculation

3SBio's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=380.452/3308.735
=0.11

3SBio's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=148.11/3300.78
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio  (OTCPK:TRSBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


3SBio LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of 3SBio's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio Business Description

Traded in Other Exchanges
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
3SBio Inc is a biotechnology company. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing, and marketing biopharmaceuticals. The core products of the Group include several biopharmaceutical drugs, TPIAO recombinant human erythropoietin rhEPO products EPIAO and SEPO, Yisaipu, Cipterbin, and a small molecule drug, Mandi. Except for minoxidil, an over-the-counter drug, the others are all older-generation biologics.

3SBio Headlines

No Headlines